09.15 |
Registration and refreshments |
09.45 |
Welcome – co-hosts Alan Jones and Roy Lilley |
10.00 |
A scene setter: the NHS after Darzi
Professor Chris Ham, professor of health policy and management, health services management centre, University of Birmingham
An exploration of the key reform drivers and their likely implications for companies.
|
10.40 |
World class commissioning: changing the paradigm?
Sophia Christie, chief executive, Birmingham East and North PCT
An ambitious vision but what does it actually mean and what might some of the implications and opportunities be for companies? |
11.20 |
Refreshments |
11.40 |
Our NHS, our future: a new NHS plan?
Nigel Edwards, policy director, NHS Confederation
The final Darzi report is another ambitious vision but will it just lead to reform fatigue? What are the implications and opportunities here for companies? |
12.20 |
Panel discussion – chaired by Alan Jones and Roy Lilley |
12.50 |
Lunch |
13.50 |
Health technology assessment in 2009/10: what do companies need to know?
Andrew Dillon, chief executive, National Institute for Health and Clinical Excellence
A final piece of the healthcare reform jigsaw in this forward looking environmental review. With a new pharmaceutical price regulation scheme and possible value-based pricing, an astute understanding of HTA will be a critical success factor in ensuring market access. What are the opportunities/threats here for companies? |
14.30 |
Delivering health gain: Investing in health, or paying for healthcare?
Dr. Peter Brambleby, director of public health, North Yorkshire and York PCT and North Yorkshire County Council
In a managed market for healthcare, what are the opportunities for companies to work with local health economies to assure health gain? What is social marketing and what is it showing? What is programme budgeting and how can it help? Where are we with measuring health outcomes? How can we leverage the wider information base? |
15.10 |
Refreshments |
15.30 |
Collaborating for health gain: joint working in 2009/10
Richard Barker, director general, The Association of the British Pharmaceutical Industry
With new guidance and a joint working toolkit, are all the pieces now in place to effect closer working or do some barriers still remain? What is the reality versus the rhetoric? |
16.10 |
Panel discussion – chaired by Alan Jones and Roy Lilley |
16.30 |
Close |
